» Articles » PMID: 36398876

Heterogeneous Natural History of Addison's Disease: Mineralocorticoid Deficiency May Predominate

Overview
Journal Endocr Connect
Specialty Endocrinology
Date 2022 Nov 18
PMID 36398876
Authors
Affiliations
Soon will be listed here.
Abstract

Autoimmune Addison's disease (AAD) is defined as primary adrenal insufficiency due to immune-mediated destruction of the adrenal cortex. This destruction of steroid-producing cells has historically been thought of as an irreversible process, with linear progression from an ACTH-driven compensated phase to overt adrenal insufficiency requiring lifelong glucocorticoid replacement. However, a growing body of evidence suggests that this process may be more heterogeneous than previously thought, with potential for complete or partial recovery of glucocorticoid secretion. Although patients with persistent mineralocorticoid deficiency despite preserved or recovered glucocorticoid function are anecdotally mentioned, few well-documented cases have been reported to date. We present three patients in the United Kingdom who further challenge the long-standing hypothesis that AAD is a progressive, irreversible disease process. We describe one patient with a 4-year history of mineralocorticoid-only Addison's disease, a patient with spontaneous recovery of adrenal function and one patient with clinical features of adrenal insufficiency despite significant residual cortisol function. All three patients show varying degrees of mineralocorticoid deficiency, suggesting that recovery of zona fasciculata function in the adrenal cortex may occur independently to that of the zona glomerulosa. We outline the current evidence for heterogeneity in the natural history of AAD and discuss possible mechanisms for the recovery of adrenal function.

Citing Articles

Addison's Disease: Diagnosis and Management Strategies.

Carsote M, Nistor C Int J Gen Med. 2023; 16:2187-2210.

PMID: 37287503 PMC: 10243343. DOI: 10.2147/IJGM.S390793.

References
1.
Chakera A, Vaidya B . Spontaneously resolving Addison's disease. QJM. 2011; 105(11):1113-5. DOI: 10.1093/qjmed/hcr162. View

2.
Napier C, Gan E, Mitchell A, Gilligan L, Aled Rees D, Moran C . Residual Adrenal Function in Autoimmune Addison's Disease-Effect of Dual Therapy With Rituximab and Depot Tetracosactide. J Clin Endocrinol Metab. 2019; 105(4). PMC: 7067544. DOI: 10.1210/clinem/dgz287. View

3.
Pearce S, Gan E, Napier C . MANAGEMENT OF ENDOCRINE DISEASE: Residual adrenal function in Addison's disease. Eur J Endocrinol. 2020; 184(2):R61-R67. PMC: 7849375. DOI: 10.1530/EJE-20-0894. View

4.
Dawoodji A, Chen J, Shepherd D, Dalin F, Tarlton A, Alimohammadi M . High frequency of cytolytic 21-hydroxylase-specific CD8+ T cells in autoimmune Addison's disease patients. J Immunol. 2014; 193(5):2118-26. PMC: 4821366. DOI: 10.4049/jimmunol.1400056. View

5.
Smans L, Zelissen P . Partial recovery of adrenal function in a patient with autoimmune Addison's disease. J Endocrinol Invest. 2008; 31(7):672-4. DOI: 10.1007/BF03345623. View